2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

4953 MYB dosage licences establishment of enhancer activity during leukemogenesis

I-Jun Lau, MD, PhD, Rebecca Sarah Maynard, MSc, PhD2, Alastair Smith, PhD3, Joe Harman4, Simona Valletta5, Yale Michaels6, Tudor Fulga, PhD7, Thomas A Milne, PhD8
1 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, Oxford Translational Myeloma Centre, Botnar Institute, University of Oxford, Oxford, United Kingdom, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
2 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
3 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
4 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
5 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
6 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
7 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
8 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Aberrant enhancer activity is a hallmark of KMT2A-rearranged (KMT2A-r) leukemia. Leukemogenesis is initiated by KMT2A fusion proteins, which impose an aberrant transcriptional and epigenetic program on hematopoietic stem and progenitor cells (HSPCs). MYB, a hematopoietic transcription factor, is a direct target of KMT2A fusion proteins and is commonly overexpressed in KMT2A-r leukemia. We have previously shown that MYB alone is sufficient to establish enhancers de novo and is required to maintain enhancer activity at key oncogenes including MYC and BCL2. Whether MYB is required at the onset of transformation, as opposed to the maintenance of established disease remains unresolved. Existing inducible systems cannot ensure that MYB repression is temporally coupled to the onset of leukemia initiation. Given that MYB is essential in normal HSPCs, its repression before transformation alters the target cell itself, whereas repression once transformation is underway interrogates maintenance rather than initiation.

We therefore engineered a conditional repression circuit in which Myb downregulation is triggered by expression of the KMT2A::MLLT3 fusion protein. Exploiting the fact that KMT2A::MLLT3 upregulates miR-196b, we inserted two tandem, perfectly complementary miR-196b response elements into the endogenous Myb 3'UTR by CRISPR-Cas9 zygote injection in C57BL/6J mice, generating a MybMRE/MRE (MRE) line in which Myb downregulation occurs only at the onset of leukemic transformation.

MRE mice were viable, fertile and phenotypically normal, with no differences in peripheral blood counts compared with age-matched wild-type (WT) mice. Following competitive transplantation, bone marrow analysis at 18 weeks showed no significant differences in stem or progenitor reconstitution. MRE cells did show increased peripheral blood reconstitution (week-4 chimerism 58.1 ± 5.6% vs 35.7 ± 6.4%, p < 0.0001, n = 9 per genotype) without lineage bias, suggesting increased downstream proliferation or differentiation. MRE cells therefore enter transformation with no competitive disadvantage.

To test the requirement for MYB during transformation, Lin− cells from MRE or WT CD45.2 mice were transduced with a retrovirus co-expressing KMT2A::MLLT3 and mCherry, and mCherry+ cells sorted and serially replated in methocellulose for three weeks before transplantation into CD45.1 recipients (n = 4 donors per genotype, 3 recipients per donor). KMT2A::MLLT3 induced miR-196b 359.5-fold versus vector control, and RNA-seq confirmed graded Myb repression in MRE versus WT cells (post transduction week 1 log2FC −0.33, FDR 5.8×10?5; week 3 log2FC −0.74, FDR 4.7×10?²7), a ~40% reduction conincident with oncogene expression, confirming repression circuit activity.

We next asked whether reduced MYB dosage impairs enhancer establishment. H3K27ac ChIPmentation at week 3, during active Myb repression, revealed differential enhancer usage at more than 100 loci, including loss of enhancer H3K27ac at the known MYB targets Myc and Bcl2, with corresponding transcriptional downregulation (log2FC −0.82, FDR 6.8×10?²4; and −0.43, FDR 1.4×10?³, respectively). Both genotypes engrafted and generated exclusively myeloid disease, but MRE recipients showed delayed engraftment (10.0 ± 4.4 vs 5.3 ± 3.1 weeks to >0.1% donor chimerism, p = 0.0086), lower leukemic burden at end-point (WCC 27.2 ± 10.3 vs 49.6 ± 29.6 ×10?/L, p = 0.048) and significantly prolonged survival (median 105 vs 67 days; log-rank p = 0.0075). Notably, Myb repression was undetectable in end-point MRE blasts (log2FC +0.20, FDR 0.996), in contrast to week 3 post transduction, and only ~200 genes were differentially expressed genome-wide, indicating that leukemias arise only from cells that escape the repression circuit and converge transcriptionally on WT disease.

Overall, our data argue that MYB dosage is required at the onset of KMT2A-r leukemogenesis, where it acts to establish enhancer activity at key oncogenes, and that even modest, transformation-restricted MYB repression imposes a selective pressure that must be escaped rather than tolerated. More broadly, this approach uses an endogenous, oncogene-induced miRNA as a cell-state sensor to confine perturbation to transformed cells within an otherwise normal animal, providing a generalizable framework for interrogating initiation-stage dependencies and for modeling the therapeutic window of pan-essential targets, with independently exchangeable sensor and target modules.

I-Jun Lau, MD, PhD: Johnson & Johnson - Honoraria; Menarini Stemline - Honoraria; Pfizer Inc. - Research Funding